Connect with us


Endometriosis, CBD and self-care: “It doesn’t get the recognition that it should”

Laura Walton started her journey with CBD after being diagnosed with endometriosis.



Endometriosis: Laura and Catherine from CBD brand MOI + ME

Two best friends, and co-founders, share how endometriosis, anxiety and friendship led to the creation of a new CBD brand with an emphasis on self-care.

Laura Walton started her journey with CBD after being diagnosed with endometriosis. She experienced chronic pain and was finally diagnosed after a collapse at work. Over the years she has had various operations including one to replant a kidney after an ovary became stuck to her urethra blocking her kidneys.

Endometriosis: A banner advert for the medical cannabis clinic

Her last operation resulted in cardiac arrest where she was forced to undergo CPR. After she recovered, she began to develop a tightness in her chest that was later diagnosed as anxiety.

Speaking with Cannabis Health News, Laura said: “I suffer from endometriosis and have had 15 operations with which comes anxiety. I also lost my mother quite suddenly in December 2016 which is when the anxiety really took hold. After her death, I went in to have a final operation, a hysterectomy for the endometriosis but I had an allergic reaction in theatre and went into cardiac arrest.”

Laura added: “I died for two minutes so when they brought me round they had done a lot of damage to my chest to do CPR. CBD oil was really my saviour and when we introduced our own balm, it really helped me to relax. CBD has helped with my grief, endometriosis pain and it has really helped my anxiety.”

Endometriosis: Laura from CBD brand MOI + ME

Laura Walton, from CBD brand MOI + ME

Endometriosis pain

Endometriosis is a painful, long-term condition where tissue similar to the lining of the womb starts to grow in other areas of the body. Symptoms may include severe period pain, heavy periods, feeling nauseous and pain during sex. Endometriosis UK estimates that it takes seven and a half years to get a diagnosis. It is the second most common gynaecological condition in the UK as it affects one in ten women in the UK.

READ MORE  Grow Pharma to launch own-brand cannabis flower

Laura said: “It’s debilitating and it doesn’t get the recognition that it should. It takes on average, eight years for a person to be diagnosed. As a female who has it, and suffers from it, my heart goes out to anyone with it.”

Recovery time for Laura after her cardiac arrest was long. She explained that the impact of the CPR on her chest has left a tightness where she couldn’t lift her arms. She also experienced anxiety tied to drinking water after doctors said her cardiac arrest may have been caused by dehydration.

“After I had the cardiac arrest, I couldn’t lift my own arms over my head because of the impact on the chest. Now, six months later, my chest is still not right and they have said it may never be right again because they depress the chest so much to restart the heart.”

CPR consists of a person placing the heel of their hand onto the chest to perform 100 to 120 compressions per minute in order to assist someone in cardiac arrest. Injuries such as broken ribs or bruising are common and it is recommended that a person continue CPR even if they fear they have broken someone’s bone.

Self-care, endometriosis and CBD

Catherine Meardon started taking CBD to boost her wellbeing. She found that her previous high powered roles in marketing and sales were quite fast-paced leading to feelings of anxiety and headaches.

She said: “I started to get tension headaches and felt overwhelmed by all the work and pressures. I find our CBD head rollers quite good for the tension headaches as it helps to subdue them. I was also there through all of Laura’s journey which is how we became friends. We’ve supported each other through everything we’ve done.”

READ MORE  Can CBD make you a better runner?

Catherine and Laura went on to found the CBD brand, MOI+ ME.  The ethos of the brand is centred around self-care and taking time out. The name, MOI + ME refers to the public face we reveal to the world that maintains we are doing ok while the reality may be different.

The product range includes rollerball, mist, bath bombs and CBD candles. The candle ‘wax’ is actually a solid oil that can be used (once the candle has been blown out) to massage the skin. Fragranced with essential oils such as jasmine and sandalwood, it can help to soothe even the most stressed-out, post-work mood. The scents included in the collection were chosen especially to help with restoring calm. They are also helpful for those with endometriosis or anxiety.

Endometriosis: A candle sitting in it blue box

Another advantage of CBD candles over more traditional forms of massage oil is that they can be used while hot or lukewarm to relax the skin.

The candles provide a nice starter product for anyone who may feel a bit daunted by CBD. While it is becoming more acceptable, there is still stigma and a lack of education around the endocannabinoid system and cannabis. Laura explained that the regulations around claims and advertising can make it difficult for brands to share their success stories.

“There is still a perception that it gets you high and it’s a bit taboo. It’s very hard to talk CBD and even to advertise because we can’t make any claims which make people nervous. I would love to be able to share my personal story on how it benefitted me but the restrictions on what we can and can’t say is a bit of a stumbling block,” she said.

READ MORE  Could CBD be the key to a healthier 2022?

“The candles are a very safe product for people who are tempted by CBD but the oil feels a bit overwhelming because you digest it into your system. Everyone burns candles at home but with this one, you can massage it into the skin. It’s quite a low dose of CBD so it’s an entry-level product without being totally overwhelmed by where to go and what to do with it.”

Endometriosis: A banner advert for subscribing to Cannabis Health News


New studies examine effects of THC and CBD on stroke

New data suggests both positive and negative effects of cannabis in stroke patients



A new study has shown that pre-treatment CBD may have a neuroprotective effect in stroke patients.

The study aimed to investigate the effect of CBD on oxidative stress and cell death which occurs in ischemic stroke patients.

It revealed that the cannabinoid may reduce the destructive effects of cell damage associated with stroke.

Ischemic strokes are the most common type of stroke. They occur when a blood clot blocks a flow of oxygen or blood to the brain. This takes place in arteries that have been narrowed or blocked over time by fatty deposits (plaques). The most common symptoms of a stroke include facial drooping on one side, not being able to lift your arms and slurred speech.

If this occurs, it is vital that a person be taken to the emergency room immediately.

The National Institute of Health Care and Excellence (NICE) estimate that there are around 100,000 strokes every year in the UK. It is also thought that 1.3 million people live with the effects of a stroke.

Stroke recovery and CBD results

The Study showed that CBD reduced the amount of infarction in those samples which had been given the cannabinoid. Infarction refers to the death of tissue as a result of a lack of blood supply and is commonly due to a blood vessel being obstructed or narrowed.

There were also differences in malondialdehyde level (MDA) – a common marker of oxidative stress – between the brains of the CBD group and the vehicle group.

It also revealed that CBD may help to protect tissue by preventing further damage.

READ MORE  Integro Medical Clinics: living with and managing arthritis pain

THC and stroke risk

Another recent study examined the effect that tetrahydrocannabinol (THC) could have on strokes. It found that it may increase the risk of a certain type of stroke among cannabis consumers.

According to findings, cannabis consumers who experience a stroke known as an aneurysmal subarachnoid haemorrhage (aSAH), are twice as likely to develop further complications.

An aSAH occurs when a weakened blood vessel bursts on the surface of the brain leading to bleeding between the brain and tissue that covers it. It can result in neurological disabilities, long-term slurred speech or even death. It is estimated that aSAH affects around eight people per 100,000 of the population each year, accounting for six per cent of first strokes.

The study by the American Stroke Association suggested there is twice the risk of developing delayed cerebral ischemia for cannabis consumers. The researchers analysed data from 1,000 patients who had received treatment for bleeding over a 12 year period. In the group of participants, 36 per cent developed cerebral ischemia and 50 per cent had moderate to severe disabilities.

When comparing the results of patients who tested positive for THC with those who did not, they found cannabis consumers were 2.7 times more likely to develop cerebral ischemia. They were also 2.8 times more likely to develop long-term moderate to severe physical disabilities.

However, compared to those who tested negative for THC, the cannabis group did not have larger aneurysms, higher blood pressures or worse stroke symptoms when admitted to the hospital. They did not have any higher cardiovascular risk factors than the negative group.

READ MORE  How I found relief from back pain with medical cannabis

Researchers are now conducting further studies in which they hope to better understand if THC can impact aneurysm formation and rupture.

Stroke: A banner advert for cannabis health news sign ups

Continue Reading


New study shows CBD may prevent Covid-19 infection

Researchers are calling for more trials to determine if CBD could be a preventative or early treatment for the virus.



Covid: A covid infection

Researchers are recommending clinical trials to examine if CBD could help to prevent Covid infection after more positive findings have been published.

Researchers from the University of Chicago have reported that CBD may stop the infection of Covid-19 by blocking its ability to replicate in the lungs.

A number of cannabinoids including CBD and THC were tested along with 7-Hydroxycannabidiol (7-OH-CBD) which is thought to be produced when cannabidiol is processed by the body.

The study found that CBD showed a significant negative association with SARS-CoV-2 positive tests in a national sample of patients who were taking  high doses of CBD, prescribed for epilepsy.

As a result of their findings, researchers are calling for more clinical trials to determine whether CBD could eventually be used as a preventative or early treatment for the virus.

Covid- Covid infection

Covid and CBD study

Researchers treated human lung cells with a non-toxic dose of CBD for two hours before exposing the cells to SARS-CoV-2 and monitoring them for the virus and the viral spike protein.

They found that, above a certain threshold concentration, CBD inhibited the virus’ ability to replicate.

Further investigation found that CBD had the same effect in two other types of cells and for three variants of SARS-CoV-2 in addition to the original strain.

CBD did not affect the ability of SARS-CoV-2 to enter the cell. Instead, CBD was effective at blocking replication early in the infection cycle and six hours after the virus had already infected the cell.

Like all viruses, SARS-CoV-2 affects the host cell by hijacking its gene expression machinery to produce more copies of itself and its viral proteins. This effect can be observed by tracking virus-induced changes in cellular RNAs. High concentrations of CBD almost completely eradicated the expression of viral RNAs.

READ MORE  UK grants second licence to grow high-THC medical cannabis

When it came to the other cannabinoids, CBD was found to be the only potentially potent agent. There was no or limited antiviral activity noted by the similar cannabinoids including THC, CBDA, CBDV, CBC or even CBG.

Marsha Rosner, PhD, professor and senior author of the study said it was a completely unexpected result, she commented: “CBD has anti-inflammatory effects, so we thought that maybe it would stop the second phase of COVID infection involving the immune system, the so-called ‘cytokine storm.’ Surprisingly, it directly inhibited viral replication in lung cells.

She added: “We just wanted to know if CBD would affect the immune system. No one in their right mind would have ever thought that it blocked viral replication, but that’s what it did.”

The researchers do caution that this is not possible with commercially available CBD. The CBD tested was high-purity and also medical grade.

However, Rosner cautioned:  “Going to your corner bakery and buying some CBD muffins or gummy bears probably won’t do anything. The commercially available CBD powder we looked at, which was off the shelf and something you could order online, was sometimes surprisingly of high purity but also of inconsistent quality. It is also hard to get into an oral solution that can be absorbed without the special, FDA-approved formulation.”

CBD and Covid studies

This is the second study to be released showing the potential for cannabinoids in Covid management and prevention.

A study by Oregon State University has revealed that the compounds cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA), may have the ability to prevent the virus that causes Covid-19 from entering human cells.

READ MORE  Making the case for medical cannabis vaping

Researchers and scientists, led by Richard van Breedan, found that a pair of cannabinoid acids bind to the SARS-CoV-2 spike protein, blocking a step in the process the virus takes for infection.

Targeting compounds that block the virus-receptor interaction has been helpful for patients with other viral infections such as HIV-1 and hepatitis.

The researchers and scientists identified the two cannabinoid acids through a screening technique, developed previously in van Breeman’s laboratory. The team also screened different botanicals such as red clover, hops, wild yam and three types of liquorice.

Continue Reading


Partner of Irish politician “six years seizure free” faces charges over medical cannabis use

John Montaine uses medical cannabis to manage his epilepsy – and is said to be six years seizure free.



Irish government medical cannabis
John Montaine, is the partner of Clare Sinn Fein TD Violet Ann Wynne.

The partner of a sitting Irish TD is contesting charges of cannabis possession, saying he uses it medicinally to manage his epilepsy.

John Montaine, who is the partner of Clare Sinn Fein TD Violet Ann Wynne, was charged with the alleged illegal possession of cannabis on February 11, 2021, at his family home, the Irish Independent reported.

Mr Montaine contests the charges and his partner Deputy Wynne has previously spoken publicly about how he uses cannabis medicinally to manage his epilepsy.

Speaking after the initial court hearing in November, Deputy Wynne said in March her partner would be “six years seizure free”.

She went on to say that it has improved his quality of life “100 per cent, without a doubt”.

“There was always some kind of issue – say John having a number of fits within the one month or losing teeth or suffering with severe migraine, but since John has been using the medicinal cannabis, he has had a better quality of life,” Deputy Wynne told the Independent.

She added: “It has also freed myself up. John would have been on disability allowance and I would have had to have been his carer but since using the medicinal cannabis, he doesn’t suffer from any of those issues any longer.”

Medical cannabis is legal in Ireland, but access to a prescription is limited.

Last year Ryan Gorman, a 26-year-old man, from Dublin, who also suffers from epilepsy, became the first patient to receive a cannabis-based medicine through the Medical Cannabis Access Programme.

Despite legislation being signed off in 2019, Ireland’s Health minister Stephen Donnelly only announced funding for it in January 2021, with the programme only becoming fully operational in November.

Four cannabis-based medicines are expected to be available through the MCAP, to people living with one of three qualifying conditions. These include intractable nausea and vomiting associated with chemotherapy, severe treatment-resistant epilepsy and spasticity associated with multiple sclerosis (MS). 

Mr Montaine’s solicitor appeared in Kilrush District Court on behalf of his client this week, where his case was adjourned until 15 March.

READ MORE  Could CBD be the key to a healthier 2022?
Continue Reading